Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5963
    +0.0014 (+0.23%)
     

  • NZD/EUR

    0.5557
    +0.0016 (+0.30%)
     

  • ALL ORDS

    7,836.80
    -100.70 (-1.27%)
     

  • ASX 200

    7,576.00
    -107.00 (-1.39%)
     

  • OIL

    84.06
    +0.49 (+0.59%)
     

  • GOLD

    2,348.80
    +6.30 (+0.27%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,695.28
    +410.74 (+2.38%)
     

  • NIKKEI 225

    38,035.17
    +406.69 (+1.08%)
     

  • NZD/JPY

    93.0710
    +0.5750 (+0.62%)
     

Company News For Sep 20, 2018

Zacks Equity Research
Updated
China's retaliatory statements over U.S. sanctions on its armed forces could lead to a possible military confrontation.

  • Tilray Inc.’s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials

  • Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its platform

  • Copart Inc.’s CPRT shares plunged 13.4% after posting fiscal fourth quarter 2018 adjusted earnings per share of $0.42 missing the Zacks Consensus Estimate of $0.47

  • Shares of AbbVie Inc. ABBV tumbled 1.7% following news that the company is facing legal challenge from a California insurer following allegations of kickbacks


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Facebook, Inc. (FB) : Free Stock Analysis Report
 
AbbVie Inc. (ABBV) : Free Stock Analysis Report
 
Copart, Inc. (CPRT) : Free Stock Analysis Report
 
Tilray, Inc. (TLRY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research